Cargando…

Caffeine for Prevention of Alzheimer’s Disease: Is the A(2A) Adenosine Receptor Its Target?

Alzheimer’s disease (AD) is the most prevalent kind of dementia with roughly 135 million cases expected in the world by 2050. Unfortunately, current medications for the treatment of AD can only relieve symptoms but they do not act as disease-modifying agents that can stop the course of AD. Caffeine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merighi, Stefania, Travagli, Alessia, Nigro, Manuela, Pasquini, Silvia, Cappello, Martina, Contri, Chiara, Varani, Katia, Vincenzi, Fabrizio, Borea, Pier Andrea, Gessi, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296091/ https://www.ncbi.nlm.nih.gov/pubmed/37371547 http://dx.doi.org/10.3390/biom13060967

Ejemplares similares

Pharmacology of Adenosine Receptors: Recent Advancements
por: Vincenzi, Fabrizio, et al.
Publicado: (2023)

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity?
por: Merighi, Stefania, et al.
Publicado: (2022)

Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy
por: Fernandez, Mercedes, et al.
Publicado: (2023)

Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets
por: Pasquini, Silvia, et al.
Publicado: (2022)

Pathophysiological Role and Medicinal Chemistry of A(2A) Adenosine Receptor Antagonists in Alzheimer’s Disease
por: Merighi, Stefania, et al.
Publicado: (2022)

A(1) Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

An Open Question: Is the A(2A) Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
por: Merighi, Stefania, et al.
Publicado: (2021)

A(2A) Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
por: Gessi, Stefania, et al.
Publicado: (2021)

The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A(1)AR Positive Allosteric Modulation
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
por: Pasquini, Silvia, et al.
Publicado: (2022)

Adenosine and Inflammation: Here, There and Everywhere
por: Pasquini, Silvia, et al.
Publicado: (2021)

Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields
por: Varani, Katia, et al.
Publicado: (2017)

Role and Function of A(2A) and A(3) Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis
por: Ravani, Annalisa, et al.
Publicado: (2017)

The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells
por: Vincenzi, Fabrizio, et al.
Publicado: (2012)

Microglia and Alzheimer’s Disease
por: Merighi, Stefania, et al.
Publicado: (2022)

Adenosinergic System Involvement in Ischemic Stroke Patients’ Lymphocytes
por: Pasquini, Silvia, et al.
Publicado: (2020)

A(2A) Adenosine Receptors Are Differentially Modulated by Pharmacological Treatments in Rheumatoid Arthritis Patients and Their Stimulation Ameliorates Adjuvant-Induced Arthritis in Rats
por: Vincenzi, Fabrizio, et al.
Publicado: (2013)

Inhibition of A(2A) Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455
por: Gessi, Stefania, et al.
Publicado: (2017)

Pulsed Electromagnetic Fields Increased the Anti-Inflammatory Effect of A(2A) and A(3) Adenosine Receptors in Human T/C-28a2 Chondrocytes and hFOB 1.19 Osteoblasts
por: Vincenzi, Fabrizio, et al.
Publicado: (2013)

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors
por: Gessi, Stefania, et al.
Publicado: (2006)

Adenosine and lymphocyte regulation
por: Gessi, Stefania, et al.
Publicado: (2007)

Therapeutic Potential of Allicin and Aged Garlic Extract in Alzheimer’s Disease
por: Tedeschi, Paola, et al.
Publicado: (2022)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

Anxiolytic properties of A(1) adenosine receptor PAMs
por: Vincenzi, Fabrizio, et al.
Publicado: (2016)

Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling
por: Ferrari, Davide, et al.
Publicado: (2022)

Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Antioxidant and Antiinflammatory Effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum Plant Extracts in Macrophage and Microglial Cells
por: Merighi, Stefania, et al.
Publicado: (2021)

The Effect of Different Storage Conditions on Phytochemical Composition, Shelf-Life, and Bioactive Compounds of Voghiera Garlic PDO
por: Tedeschi, Paola, et al.
Publicado: (2023)

A(2A )and A(3 )adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release
por: Varani, Katia, et al.
Publicado: (2011)

A(2A) adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus
por: Bortoluzzi, Alessandra, et al.
Publicado: (2016)

Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
por: Papa, Alessandro, et al.
Publicado: (2022)

The Role of Adenosine Receptors in Psychostimulant Addiction
por: Ballesteros-Yáñez, Inmaculada, et al.
Publicado: (2018)

A(3) Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
por: Vincenzi, Fabrizio, et al.
Publicado: (2021)

Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A(2A) Receptor Inverse Agonists
por: Varano, Flavia, et al.
Publicado: (2020)

Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists
por: Catarzi, Daniela, et al.
Publicado: (2019)

Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
por: Merighi, Stefania, et al.
Publicado: (2021)

A(2A) adenosine receptors are involved in the reparative response of tendon cells to pulsed electromagnetic fields
por: Colombini, Alessandra, et al.
Publicado: (2020)

4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives
por: Catarzi, Daniela, et al.
Publicado: (2022)

The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A(1) and A(2A) receptor affinity and selectivity profiles
por: Squarcialupi, Lucia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p5vr02ci32hqhdq8u3tqgpt3bj